Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Loading...

Monday, November 23, 2020

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Cancer shared this article with you from Inoreader
Condition:   Cancer Intervention:   Biological: LVGN7409 Sponsor:   Lyvgen Biopharma Holdings Limited Not yet recruiting (Source: ClinicalTrials.gov)
View on the web
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)